The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients

CAPS Registry Project Group

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Objectives. The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry. Methods. Patients from the CAPS Registry were grouped based on their treatments: triple therapy; drugs included in the triple therapy but in different combinations; and none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups. Results. The CAPS Registry cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 54 episodes (10.3%), a total of 471 patients with CAPS were included [mean (S.D.) age 38.5 years (17); 68.2% female primary APS patients 62%]. Overall, 174 (36.9%) patients died. Triple therapy was prescribed in 189 episodes (40.1%), other combinations in 270 (57.3%) and none of those treatments in 12 episodes (2.5%); the mortality rate in the three groups was 28.6, 41.1 and 75%, respectively. Triple therapy was positively associated with a higher chance of survival when compared with non-treatment [adjusted odds ratio (OR) = 9.7, 95% CI: 2.3, 40.6] or treatment with other combinations of drugs included in the triple therapy (adjusted OR = 1.7, 95% CI: 1.2, 2.6). No statistical differences were found between patients that received triple therapy with plasma exchange or IVIGs (P = 0.92). Conclusion. Triple therapy is independently associated with a higher survival rate among patients with CAPS.

Original languageEnglish (US)
Pages (from-to)1264-1270
Number of pages7
JournalRheumatology (United Kingdom)
Volume57
Issue number7
DOIs
StatePublished - Jul 1 2018

Keywords

  • Antiphospholipid syndrome
  • Catastrophic antiphospholipid syndrome
  • Immunoglobulins
  • Mortality
  • Plasma exchange
  • Survival rate
  • Systemic lupus erythematosus
  • Treatment
  • Triple therapy

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients'. Together they form a unique fingerprint.

  • Cite this